该化合物是一种主要用于治疗勃起功能障碍的药物化合物,是一种五类磷酸酯(PDE5)的选择性抑制剂,它通过增加阴茎的血液流以适应性刺激而增强勃起功能;该物质似乎是白色的,白色的,脱白的晶体粉,在水中可溶解,它有利于以口服剂量形式配制. Vardenafil di hitrogide 有一种分子配方,它反映了其复杂结构,包含有助于其药理活动的各种功能组.该化合物表现出相对快速的行动开始,通常在施用后30至60分钟内,其效果可以持续数小时.与其他PDE5抑制剂一样,重要的是考虑潜在的副作用,其中可能包括头痛,冲洗和胃肠扰动.此外,在服用硝酸盐或某些心血管疾病的病人中,应该谨慎使用芳化剂,因为它可以导致显著的相互作用.
1: Ashour AE, Rahman AF, Kassem MG. Vardenafil dihydrochloride. Profiles Drug Subst Excip Relat Methodol. 2014;39:515-44. doi: 10.1016/B978-0-12-800173-8.00009-X. Review. Review. Russian. doi: 10.1016/j.jpba.2012.02.014. Epub 2012 Mar 8. Review. doi: 10.2165/11208270-000000000-00000. Review. doi: 10.1517/14656566.2011.584064. Review. Review. Chinese. Epub 2009 Dec 29. Review. 8: Rice KR, Dean RC. Vardenafil: efficacy, tolerability and future directions. Expert Opin Drug Metab Toxicol. 2009 May;5(5):553-62. doi: 10.1517/17425250902884108 . Review. doi: 10.1111/j.1464-410X.2008.08267.x. Epub 2008 Dec 8. Review. Erratum in: BJU Int. 2011 Apr;107(7):1166. doi: 10.1111/j.1742-1241.2008.01852.x. Review. Review. Epub 2006 Dec 21. Review. Review. Chinese. Review. Epub 2005 Jan 26. Review. Review. Review. Chinese. Review. Review. Review.
合成参考文献
参考文献:10.1556/oh.2010.28800 摘要:Kopa Z, Romics I. [Therapy of erectile dysfunction]. Orv Hetil. 2010 Feb 27;151(9):354–7. doi: 10.1556/oh.2010.28800. 参考文献:10.1111/j.1743-6109.2011.02383.x 摘要:Schneider T, Gleissner J, Merfort F, Hermanns M, Beneke M, Ulbrich E. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial. J Sex Med. 2011 Oct;8(10):2904–11. doi: 10.1111/j.1743-6109.2011.02383.x.